Paul Tudor Jones Spring Works Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$18.94 - $37.24 $361,242 - $710,278	19,073 New	19,073 $696,000
Q2 2023 Aug 14, 2023	BUY	$23.15 - $32.71 $490,710 - $693,353	21,197 New	21,197 $555,000
Q2 2022 Aug 15, 2022	BUY	$18.36 - $60.07 $466,876 - $1.53 Million	25,429 Added 161.4%	41,184 $1.01 Million
Q1 2022 May 16, 2022	BUY	$48.97 - $65.46 $771,522 - $1.03 Million	15,755 New	15,755 $889,000
Q2 2021 Aug 16, 2021	SELL	$67.45 - $85.63 $541,690 - $687,694	-8,031 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$65.1 - $93.59 $522,818 - $751,621	8,031 New	8,031 $591,000
Q4 2019 Feb 14, 2020	SELL	$17.74 - $39.52 $182,296 - $406,107	-10,276 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$18.8 - $27.82 $193,188 - $285,878	10,276 New	10,276 $223,000

238

70M

144K

257K

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.34B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.